Susan Halabi, PhD, Duke University, Durham, NC, discusses the identification of intermediate clinical endpoints that could serve as surrogate for overall-survival (OS) for patients with prostate cancer. Although OS is the favored clinical endpoint for clinical trials in oncology, it requires a large population of patients and long-term patient follow-up. Additionally, patients may receive treatment following progression which could confound the estimation of treatment effect and OS results. Radiographic progression-free survival (rPFS) and clinical progression-free survival (cPFS) were identified in the first phase of the project as viable surrogates for OS and were validated in an analysis of over 8500 patients. Next, data will be explored on treatment of patients with androgen receptor therapies (ADTs) to further validate the surrogate endpoints prior to investigation in clinical trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
